Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Interim Cheif Legal Officer | September 29, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date September 29, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 11,943 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,943 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.70 · Expires 2027-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 4,377 having vested on March 3, 2021. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.98 · Expires 2027-05-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020 and 2,191 having vested on May 24, 2021. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on November 15, 2023, with 8,370 vested on each of November 15, 2024, November 15, 2025, 8,370 vesting on November 15, 2026, and 8,372 vesting on November 15, 2027. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on March 4, 2024, with 8,370 vested on each of March 4, 2025 and March 4, 2026, 8,370 vesting on March 4, 2027, and 8,372 vesting on March 4, 2028. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6: Restricted share units were granted on March 5, 2025, with 3,573 vested on March 5, 2026, and 3,573 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7: Restricted share units were granted on March 4, 2026, with 3,418 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 3,419 vesting on March 4, 2030. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-29 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8: Restricted share units were granted on March 3, 2023, with 7,768 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026 and 7,771 vesting on March 3, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 4,377 having vested on March 3, 2021.
F2: Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020 and 2,191 having vested on May 24, 2021.
F3: Restricted share units were granted on November 15, 2023, with 8,370 vested on each of November 15, 2024, November 15, 2025, 8,370 vesting on November 15, 2026, and 8,372 vesting on November 15, 2027.
F4: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F5: Restricted share units were granted on March 4, 2024, with 8,370 vested on each of March 4, 2025 and March 4, 2026, 8,370 vesting on March 4, 2027, and 8,372 vesting on March 4, 2028.
F6: Restricted share units were granted on March 5, 2025, with 3,573 vested on March 5, 2026, and 3,573 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.
F7: Restricted share units were granted on March 4, 2026, with 3,418 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 3,419 vesting on March 4, 2030.
F8: Restricted share units were granted on March 3, 2023, with 7,768 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026 and 7,771 vesting on March 3, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 11:57 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023532 · ownership.xml · derivative · entry 2 Bergwerk Dov · CIK 0001997381 · Acting Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 6,653 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 6,653 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:57 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023532 · ownership.xml · nonDerivative · entry 1 Bergwerk Dov · CIK 0001997381 · Acting Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 12:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 33,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055446 · doc4.xml · derivative · entry 1 Bergwerk Dov · CIK 0001997381 · Acting Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,482 Underlying: Ordinary Shares · 33,482 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on November 15, 2023, with 8,370 vesting on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027. F2 · derivative.expiration_date: Restricted share units were granted on November 15, 2023, with 8,370 vesting on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.